BCL2 and ovarian carcinoma: Previous studies indicated BCL2 to be related to paclitaxel resistance in ovarian cancer (Yin et al, 2021), and up-regulation of BCL2L1 has been implicated in platinum and PARP inhibitor resistance in ovarian cancer (Guo et al, 2021).